Salt Lake City-based Huntsman Cancer Institute at the University of Utah will be the first U.S. academic medical center to manufacture a novel prostate cancer imaging drug, flotufolastat F 18.
The drug was developed by Blue Earth Diagnostics and will be manufactured through Huntsman Cancer Institute’s Center for Quantitative Cancer Imaging and Theranostics, according to a Feb. 10 news release from the institute.
Flotufolastat F 18, also known as Posluma, enables more accurate detection and staging of prostate cancer tumors by binding to cells that express a prostate-specific membrane antigen.
Posluma will be the third prostate-specific membrane antigen drug manufactured at Huntsman Cancer Institute, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
